PVI
ACRS icon

Pura Vida Investments’s Aclaris Therapeutics ACRS Stock Holding History

Pura Vida Investments’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-100,000
Closed -$647K – 217
2020
Q4 		$647K Buy
+100,000
New +$422K 0.02% 168

Other funds holding ACRS

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Pura Vida Investments's ACRS Position: Q1 2022 in Review

Pura Vida Investments sold out of Aclaris Therapeutics (ACRS) in Q1 2022, closing a stake of 48,266 shares — an estimated $702K sold.

Pura Vida Investments first reported a position in ACRS in Q4 2020 and held it in 3 quarters. The position peaked at $4.43M in Q1 2021. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2022.

  • Pura Vida Investments reported no remaining Aclaris Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Pura Vida Investments sold 48,266 Aclaris Therapeutics shares in Q1 2022, an estimated $702K.
  • Pura Vida Investments first reported a position in Aclaris Therapeutics in Q4 2020 and held it in 3 quarters.
  • Pura Vida Investments's Aclaris Therapeutics position peaked at $4.43M in Q1 2021.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2022.

Based on Pura Vida Investments's 13F filing for Q1 2022, filed 16 May 2022.